Introduction to Anti-Disease-Specific Target Antibody Discovery by Premade Antibody Library

Therapeutic antibodies are an important part of the biopharmaceutical field. More than a hundred antibody drugs have been approved for marketing, and they are widely used to treat a wide range of human diseases. Common mechanisms of action of antibody drugs include disruption of ligand-receptor interactions, removal of target cells through antibody-dependent cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, bispecific antibody T-cell splicers, down-regulation of receptors through enhanced internalization and degradation, and targeted drug delivery. As scientists' research in the field of antibody becomes more and more in-depth, antibody preparation technology is also breaking through and developing, with the emergence of hybridoma monoclonal antibody technology, phage library display technology, single B-cell preparation antibody technology, and all-human antibody screening technology. Based on our rich field experience and advanced research platform, Creative Biolabs provides comprehensive services to support premade antibody library screening and anti-disease-specific target antibody discovery.

Anti-Disease-specific Target Antibody

As antibody drugs are researched, they have come to play a role in the treatment of more and more diseases. And the corresponding methods of antibody discovery are maturing, such as antibody discovery for immunotherapy, antibody discovery for autoimmune diseases, and coronavirus (COVID-19) antibody discovery.

Relevant research suggests that blocking the neonatal fragment crystallizable (Fc) receptor (FcRn) may be able to potentially treat autoimmune diseases by removing IgG and the immune complexes it forms. Blocking FcRn reduces levels of IgG (the most common antibody in the blood) in humans, which plays a key role in the body's defense against infections by binding to viruses or bacteria but has also been linked to the development of autoimmune diseases such as lupus and pemphigus. IgG forms immune complexes with antigens, which can further contribute to autoimmune diseases. A study evaluated the effects of the antibody SYNT001 (FcGn Blocking Monoclonal Antibody) on the IgG and IgG immune complexes through studies in mice, non-human primates, and humans. The results of this study found that SYNT001 reduced the levels of IgG and IgG immune complexes during circulation and also inhibited the ability of the immune complexes to activate the body's immune system. This drug candidate was well tolerated in phase 1 clinical trials. Therefore, FcRn antibody therapy is a promising avenue for the treatment of autoimmune diseases.

Reports suggest that XmAb 5871 is also a potential antibody drug for the treatment of autoimmune diseases. It is a novel bifunctional antibody capable of targeting both FcγRIIb, which inhibits B cell activity, and CD19 antigen, which is expressed by B cells. By modifying the Fc end of the monoclonal antibody that binds to the CD19 antigen, the researchers increased its affinity for FcγRIIb by 400-fold. Whereas FcγRIIb is a receptor that inhibits B-cell function, when XmAb 5871 binds to the CD19 antigen on the surface of a B-cell, its Fc end automatically binds to FcγRIIb on the same cell, thereby inhibiting B-cell receptor-mediated B-cell activation and proliferation. Early clinical studies have shown that XmAb 5871 effectively inhibits B cell function without cell depletion, producing encouraging therapeutic results in patients with a variety of autoimmune diseases.

Creative Biolabs has a wealth of knowledge and experience in premade antibody library screening. We would be happy to share with you our knowledge and experience in premade phage display human antibody library construction and anti-disease-specific target antibody discovery.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: